Amide local anesthetic (long-acting)

Plain-language summaryIntrigue 65 / 100

Bupivacaine (Marcaine, Sensorcaine) is a long-acting amide local anesthetic introduced in 1965, the n-butyl analog of mepivacaine sharing the pipecoloxylidide scaffold. The longer alkyl chain confers higher lipid solubility, longer duration (4 to 8 hours), and greater protein binding. It is sold as a racemate. The major safety story is cardiotoxicity from inadvertent intravascular injection during regional anesthesia: the (R)-enantiomer binds cardiac sodium channels tightly and dissociates slowly, producing ventricular arrhythmias and refractory cardiovascular collapse that historically resisted standard ACLS. Intravenous lipid emulsion (Intralipid 20 percent, 1.5 mL/kg bolus then infusion) is the rescue therapy, supported by case series and animal data showing reduced collapse mortality. The cardiotoxicity drove development of the (S)-enantiomer levobupivacaine. Still widely used for spinal, epidural, peripheral nerve block, and obstetric epidural. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

39/100

A decades-old clinical anesthetic whose main research legacy is motivating safer successor compounds

Look, bupivacaine is a real drug with a real clinical record. Synthesized in 1957, in clinical use since 1965, it’s one of the most-administered local anesthetics in the world. That pedigree earns it serious points on evidence quality and translational signal, and we’re not going to pretend otherwise. But the Kodiac library exists to surface compounds worth bench time right now, and bupivacaine is basically the opposite of that.

The mechanism is about as well-understood as anything in pharmacology. Voltage-gated sodium channel block, state-dependent, slowly dissociating from the inactivated channel state. The slow dissociation is both the feature (long duration) and the bug (cardiac sodium channels don’t recover during the refractory period, producing the arrhythmogenic pattern that made inadvertent intravascular injection a genuine clinical catastrophe before Intralipid rescue protocols were established). None of this is new. This is textbook content that anesthesia residents learn in their first month. Theres nothing left to discover about the core mechanism.

The differentiation case is weak. As a racemate, bupivacaine carries the (R)-enantiomer’s full cardiotoxic burden. Levobupivacaine, the pure (S)-form, strips out most of that risk while preserving the duration. Ropivacaine, a propyl analog with a similar profile, dominates much of the regional anesthesia market with a better cardiac safety window. So the racemic bupivacaine story is, at this point, mostly historical: it defined the problem that the successors solved. If you’re studying cardiac sodium channel enantioselectivity or building a model of local anesthetic-induced cardiotoxicity, bupivacaine is a useful reference compound. Thats roughly the extent of its bench value in a modern research program.

The lipid emulsion rescue literature is genuinely interesting and bupivacaine is the standard model compound for studying Intralipid pharmacokinetics in lipid sink rescue scenarios. That’s real, narrow bench utility. Outside of that niche, there’s no active research frontier here. No novel indication with signal, no emerging mechanism story, no reformulation angle that changes what we think about the molecule. The compound is exactly what it looks like: a mature clinical tool that shaped regional anesthesia and then ceded the frontier to its own descendants.

We rate it for what it is. The clinical evidence base is massive and the human signal is ironclad, which is why evidence and translational scores pull the number off the floor. But novelty is nearly zero, differentiation is poor relative to current alternatives, and bench value is limited to narrow mechanistic reference work. That produces a 39, and honestly that feels exactly right for a compound whose most interesting research contribution was being cardiotoxic enough to demand something better.

Novelty: 12
Mechanism promise: 22
In-category differentiation: 28
Evidence quality: 78
Translational signal: 75
Research bench value: 35

Rationale Bupivacaine scores high on evidence and translational signal because it’s an approved, widely-used drug with 60-plus years of clinical literature, but novelty and mechanism are basement-level: Na-channel block is well-characterized, the racemate has been superseded by levobupivacaine and ropivacaine on safety grounds, and the bench utility is narrow. The calculated overall of 39 reflects a compound that is clinically indispensable but a poor research target in 2026.

Amide local anesthetic (long-acting)

A long-acting butyl-substituted pipecoloxylidide racemic local anesthetic with high cardiotoxicity that motivated development of the (S)-enantiomer levobupivacaine.

Abstract

Bupivacaine (1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 2180-92-9; molecular formula C18H28N2O; molecular weight 288.43) is a long-acting amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in 1957 and introduced clinically in 1965 (Marcaine, Sensorcaine). The compound is the n-butyl analog of mepivacaine and shares the pipecoloxylidide scaffold; the longer alkyl chain confers higher lipid solubility, longer duration, and greater protein binding. Bupivacaine is sold as a racemate of (R)- and (S)-enantiomers; the cardiotoxicity that distinguishes bupivacaine from shorter-acting amides is enantioselectively driven by the (R)-enantiomer, which has higher affinity for cardiac sodium channels and longer dissociation kinetics. Mechanism is voltage-gated sodium channel block, state-dependent and slowly dissociating, the slow kinetics underlying both the prolonged neural block and the elevated arrhythmogenic risk relative to lidocaine. Onset for infiltration is 5 to 10 minutes; duration is 4 to 8 hours, longer with epinephrine adjunct. Maximum recommended dose is 2.5 mg/kg without epinephrine and 3 mg/kg with epinephrine. The principal historical safety concern is cardiac arrest from inadvertent intravascular injection during regional anesthesia: bupivacaine binds the cardiac sodium channel and dissociates slowly, producing ventricular arrhythmias and refractory cardiovascular collapse that proved historically resistant to standard ACLS algorithms. Intravenous lipid emulsion (Intralipid 20 percent, 1.5 mL/kg bolus then 0.25 mL/kg/min infusion) is the rescue therapy, supported by case series and animal data showing reduction in cardiovascular collapse mortality. Bupivacaine remains widely used for surgical regional anesthesia (spinal, epidural, peripheral nerve block) and obstetric epidural analgesia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1309Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Amide local anesthetic (long-acting)

Bupivacaine

Abstract

Read the full monograph